What’s New for Biologics | FDA

What’s New for Biologics | FDA

Posted: 3/2/2020

• Statistical Review - FLUAD QUADRIVALENT
• February 20, 2020 Clinical Review - FLUAD QUADRIVALENT

3/3/2020	Complete List of Licensed Products and Establishments
3/3/2020	Complete List of Substantially Equivalent 510(k) Device Applications
3/3/2020	Complete List of Currently Approved Premarket Approvals (PMAs)
3/3/2020	Complete List of Currently Approved NDA and ANDA Application Submissions
3/2/2020	Statistical Review - FLUAD QUADRIVALENT
3/2/2020	February 20, 2020 Clinical Review - FLUAD QUADRIVALENT
2/27/2020	February 26, 2020 Approval Letter - ODACTRA
2/25/2020	Synonymous mutation increases in vitro production and activity of enzyme that reduces blood clotting
2/25/2020	Determining susceptibility of influenza A viruses to first-line immune response by pulmonary surfactant protein D (SP-D)
2/25/2020	Universal test for assessing potency of inactivated poliovirus vaccines could facilitate their global production and availability
2/25/2020	Allergenic Products Advisory Committee May 15, 2020 Meeting Announcement
2/21/2020	February 21, 2020 Approval Letter - FLUAD QUADRIVALENT
2/21/2020	February 20, 2020 Approval Letter - Gardasil 9
2/21/2020	Final Agenda - Facilitating End-to-End Development of Individualized Therapeutics
2/21/2020	February 20, 2020 Approval Letter - MENVEO
2/20/2020	January 31, 2020 Summary Basis for Regulatory Action - AUDENZ
2/19/2020	January 31, 2020 Summary Basis for Regulatory Action - PALFORZIA
2/19/2020	2020 Biological Device Application Approvals
2/19/2020	2020 Biological License Application Supplement Noteworthy Approvals
2/19/2020	2020 Biological License Application Approvals
2/14/2020	Direct Recall Classification Program
2/14/2020	Electronic Submission of Biological Product Deviation Reports (eBPDR)
2/14/2020	Biological Product Deviations
2/14/2020	General Instructions for Completing the Biological Product Deviation Report (BPDR) - Form FDA 3486
2/14/2020	Instructions for Using the eBPDR System
2/14/2020	Important Information for Human Cell, Tissue, or Cellular or Tissue-based Product (HCT/P) Establishments Regarding the 2019 Novel Coronavirus Outbreak
2/14/2020	February 13, 2020 Approval Letter - VAXCHORA
2/14/2020	Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2020
2/13/2020	BK190317 - PurePRP SupraPhysiologic Concentrating System
2/13/2020	February 10, 2020 Untitled Letter - RejuvaYou Medical Corporation
2/13/2020	February 12, 2020 Approval Letter - Procleix Babesia Assay
2/13/2020	Blood Products Advisory Committee April 2-3, 2020 Meeting Announcement
2/13/2020	23rd US-Japan Cellular and Gene Therapy Conference
2/11/2020	eSubmitter Application History
2/11/2020	BK190413 - CompoMat G5 Plus and CompoMaster Net G5 Plus System
2/10/2020	January 17, 2020 Approval Letter - cobas MPX Test
2/7/2020	February 7, 2020 Approval Letter - Fluzone Quadrivalent Southern Hemisphere
2/7/2020	February 6, 2020 Approval Letter - FluLaval
2/6/2020	CBER Vacancy: Staff Fellow/Visiting Associate – Vascular Biology
2/5/2020	Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II); Guidance for Industry
2/4/2020	Important Information for Blood Establishments Regarding the Novel Coronavirus Outbreak